CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Madrigal Pharmaceuticals, Inc. - MDGL CFD

    236.12
    0.52%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.97
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Madrigal Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 234.91
    Open* 236.91
    1-Year Change* 226.28%
    Day's Range* 233.18 - 243.65
    52 wk Range 57.21-322.67
    Average Volume (10 days) 490.55K
    Average Volume (3 months) 9.70M
    Market Cap 3.72B
    P/E Ratio -100.00K
    Shares Outstanding 19.74M
    Revenue N/A
    EPS -19.24
    Dividend (Yield %) N/A
    Beta -0.50
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 234.91 14.05 6.36% 220.86 236.79 219.89
    Dec 4, 2023 221.32 13.68 6.59% 207.64 221.77 207.64
    Dec 1, 2023 212.98 11.45 5.68% 201.53 213.11 195.87
    Nov 30, 2023 203.12 2.30 1.15% 200.82 208.29 199.98
    Nov 29, 2023 197.23 5.50 2.87% 191.73 200.05 189.12
    Nov 28, 2023 190.81 -2.86 -1.48% 193.67 195.41 187.38
    Nov 27, 2023 196.93 4.95 2.58% 191.98 197.61 190.40
    Nov 24, 2023 194.32 8.17 4.39% 186.15 200.25 186.15
    Nov 22, 2023 190.09 -2.15 -1.12% 192.24 195.94 186.13
    Nov 21, 2023 188.22 3.45 1.87% 184.77 190.55 181.60
    Nov 20, 2023 189.71 13.81 7.85% 175.90 190.52 174.89
    Nov 17, 2023 176.53 6.64 3.91% 169.89 176.68 164.94
    Nov 16, 2023 168.50 1.61 0.96% 166.89 170.48 159.89
    Nov 15, 2023 161.55 5.65 3.62% 155.90 174.79 154.91
    Nov 14, 2023 156.37 2.91 1.90% 153.46 156.62 150.24
    Nov 13, 2023 145.91 9.99 7.35% 135.92 146.69 135.01
    Nov 10, 2023 138.51 1.60 1.17% 136.91 138.82 134.81
    Nov 9, 2023 136.25 -7.16 -4.99% 143.41 144.17 133.73
    Nov 8, 2023 143.21 -6.69 -4.46% 149.90 151.57 142.06
    Nov 7, 2023 151.92 5.02 3.42% 146.90 153.90 145.46

    Madrigal Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Wednesday, February 21, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Madrigal Pharmaceuticals Inc Earnings Release
    Q4 2023 Madrigal Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 293.571 242.482 206.673 94.972 40.682
    Selling/General/Admin. Expenses, Total 48.13 37.318 21.864 22.648 15.293
    Research & Development 245.441 205.164 184.809 72.324 25.389
    Operating Income -293.571 -242.482 -206.673 -94.972 -40.682
    Interest Income (Expense), Net Non-Operating -1.779 0.363 4.329 11.024 7.671
    Net Income Before Taxes -295.35 -241.846 -202.244 -83.948 -32.811
    Net Income After Taxes -295.35 -241.846 -202.244 -83.948 -32.811
    Net Income Before Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
    Net Income -295.35 -241.846 -202.244 -83.948 -32.811
    Income Available to Common Excl. Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
    Income Available to Common Incl. Extra. Items -295.35 -241.846 -202.244 -83.948 -32.811
    Diluted Net Income -295.35 -241.846 -202.244 -83.948 -32.811
    Diluted Weighted Average Shares 17.1372 16.5352 15.4466 15.3947 14.7967
    Diluted EPS Excluding Extraordinary Items -17.2344 -14.6261 -13.0931 -5.45306 -2.21745
    Diluted Normalized EPS -17.2344 -14.6261 -13.0931 -5.45306 -2.21745
    Other, Net 0 0.273 0.1 0 0.2
    Total Extraordinary Items 0 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 86.45 78.336 85.299 80.412 70.273
    Selling/General/Admin. Expenses, Total 17.845 16.182 14.557 12.141 11.774
    Research & Development 68.605 62.154 70.742 68.271 58.499
    Operating Income -86.45 -78.336 -85.299 -80.412 -70.273
    Interest Income (Expense), Net Non-Operating 0.65 1.44 -0.606 -0.785 -0.457
    Other, Net 0 0 0
    Net Income Before Taxes -85.8 -76.896 -85.905 -81.197 -70.73
    Net Income After Taxes -85.8 -76.896 -85.905 -81.197 -70.73
    Net Income Before Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
    Net Income -85.8 -76.896 -85.905 -81.197 -70.73
    Income Available to Common Excl. Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
    Income Available to Common Incl. Extra. Items -85.8 -76.896 -85.905 -81.197 -70.73
    Diluted Net Income -85.8 -76.896 -85.905 -81.197 -70.73
    Diluted Weighted Average Shares 18.3109 18.1879 17.2386 17.1034 17.1034
    Diluted EPS Excluding Extraordinary Items -4.68572 -4.22786 -4.98329 -4.74742 -4.13544
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -4.68572 -4.22786 -4.98329 -4.74742 -4.13544
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 361.369 271.684 285.163 440.197 485.201
    Cash and Short Term Investments 358.774 270.346 284.149 439.045 483.718
    Cash & Equivalents 331.549 36.269 54.004 46.697 57.379
    Short Term Investments 27.225 234.077 230.145 392.348 426.339
    Total Receivables, Net
    Prepaid Expenses 2.595 1.338 1.014 1.152 1.483
    Total Assets 362.572 273.332 286.995 442.056 485.428
    Property/Plant/Equipment, Total - Net 1.203 1.648 1.832 1.859 0.227
    Total Current Liabilities 115.894 76.838 46.557 25.13 8.444
    Accounts Payable 23.831 21.38 1.017 1.178 2.487
    Accrued Expenses 92.063 55.458 45.54 23.952 5.957
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 165.183 77.225 47.025 25.491 8.444
    Total Long Term Debt 49.289 0 0 0 0
    Total Equity 197.389 196.107 239.97 416.565 476.984
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.002 0.002 0.002 0.002 0.002
    Additional Paid-In Capital 1160.08 863.495 665.385 639.567 616.573
    Retained Earnings (Accumulated Deficit) -962.66 -667.31 -425.464 -223.22 -139.272
    Other Equity, Total -0.032 -0.08 0.047 0.216 -0.319
    Total Liabilities & Shareholders’ Equity 362.572 273.332 286.995 442.056 485.428
    Total Common Shares Outstanding 18.1025 17.1034 15.5082 15.4291 15.409
    Other Liabilities, Total 0 0.387 0.468 0.361
    Long Term Debt 49.289
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 235.469 301.595 331.284 361.369 157.112
    Cash and Short Term Investments 232.351 298.418 329.477 358.774 153.192
    Cash & Equivalents 51.385 77.196 113.308 331.549 41.112
    Short Term Investments 170.296 221.222 216.169 27.225 93.852
    Prepaid Expenses 3.118 3.177 1.807 2.595 3.92
    Total Assets 237.964 302.461 332.449 362.572 158.644
    Property/Plant/Equipment, Total - Net 2.495 0.866 1.165 1.203 1.532
    Total Current Liabilities 99.665 99.706 98.348 115.894 98.92
    Accounts Payable 16.542 17.534 12.128 23.831 18.562
    Accrued Expenses 83.123 82.172 86.22 92.063 80.358
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 215.715 198.955 182.313 165.183 147.974
    Total Long Term Debt 114.727 99.249 83.965 49.289 48.983
    Other Liabilities, Total 1.323 0 0.071
    Total Equity 22.249 103.506 150.136 197.389 10.67
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.002 0.002 0.002 0.002 0.002
    Additional Paid-In Capital 1246.39 1228.95 1189.78 1160.08 887.66
    Retained Earnings (Accumulated Deficit) -1224.1 -1125.36 -1039.56 -962.66 -876.755
    Other Equity, Total -0.042 -0.089 -0.086 -0.032 -0.237
    Total Liabilities & Shareholders’ Equity 237.964 302.461 332.449 362.572 158.644
    Total Common Shares Outstanding 18.4942 18.459 18.2831 18.1025 17.1034
    Cash 10.67 18.228
    Long Term Debt 114.727 99.249 83.965 49.289 48.983
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -295.35 -241.846 -202.244 -83.948 -32.811
    Cash From Operating Activities -224.857 -183.917 -157.561 -41.624 -25.507
    Cash From Operating Activities 0.467 0.405 0.471 0.112 0.096
    Non-Cash Items 32.422 26.873 20.73 22.759 13.489
    Changes in Working Capital 37.604 30.651 23.482 19.453 -6.281
    Cash From Investing Activities 206.686 -5.055 159.78 30.707 -380.076
    Capital Expenditures -0.217 -0.209 -0.334 -0.172 -0.022
    Other Investing Cash Flow Items, Total 206.903 -4.846 160.114 30.879 -380.054
    Cash From Financing Activities 313.451 171.237 5.088 0.235 314.335
    Financing Cash Flow Items -0.886 0
    Issuance (Retirement) of Stock, Net 264.337 171.237 5.088 0.235 314.335
    Net Change in Cash 295.28 -17.735 7.307 -10.682 -91.248
    Issuance (Retirement) of Debt, Net 50
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -76.896 -295.35 -209.445 -128.248 -57.518
    Cash From Operating Activities -84.067 -224.857 -166.342 -107.273 -49.913
    Cash From Operating Activities 0.124 0.467 0.338 0.217 0.107
    Non-Cash Items 11.683 32.422 24.034 15.599 7.477
    Changes in Working Capital -18.978 37.604 18.731 5.159 0.021
    Cash From Investing Activities -186.864 206.686 140.299 75.162 55.926
    Capital Expenditures -0.035 -0.217 -0.188 -0.155 -0.052
    Other Investing Cash Flow Items, Total -186.829 206.903 140.487 75.317 55.978
    Cash From Financing Activities 52.69 313.451 49.114 49.114 0
    Issuance (Retirement) of Stock, Net 17.903 264.337 0 0 0
    Net Change in Cash -218.241 295.28 23.071 17.003 6.013
    Financing Cash Flow Items -0.213 -0.886 -0.886 -0.886
    Issuance (Retirement) of Debt, Net 35 50 50 50
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Janus Henderson Investors Investment Advisor/Hedge Fund 15.4394 3042661 1558535 2023-09-29 LOW
    Baker Bros. Advisors LP Hedge Fund 7.8404 1545113 0 2023-10-03 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 7.6883 1515151 -151515 2023-06-30 LOW
    Bay City Capital L.L.C. Venture Capital 7.6712 1511782 0 2023-03-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.4237 1462998 47070 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.7127 928734 78587 2023-06-30 LOW
    SQN, L.L.C. Corporation 3.3264 655540 0 2023-03-31 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.7592 543759 23945 2023-06-30 LOW
    Craves (Frederick B) Individual Investor 2.3877 470556 1198 2023-06-15 LOW
    Assenagon Asset Management S.A. Investment Advisor 2.3685 466766 -49822 2023-06-30 HIGH
    Marshall Wace LLP Investment Advisor/Hedge Fund 2.3374 460644 -81120 2023-06-30 HIGH
    Taub (Rebecca A) Individual Investor 2.2061 434758 -20001 2023-03-31 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.8832 371116 347448 2023-06-30 LOW
    Paulson & Co. Inc. Hedge Fund 1.777 350200 350200 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.7704 348887 86654 2023-06-30 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.6317 321569 142579 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 1.5374 302987 -347575 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3768 271319 23262 2023-06-30 LOW
    Artisan Partners Limited Partnership Investment Advisor 1.1675 230090 14320 2023-06-30 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 1.1243 221562 221562 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Madrigal Pharmaceuticals, Inc. Company profile

    About Madrigal Pharmaceuticals Inc

    Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.

    Equity composition

    Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.

    Industry: Bio Therapeutic Drugs

    200 Barr Harbor Dr Ste 400
    WEST CONSHOHOCKEN
    PENNSYLVANIA 19428-2978
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,028.26 Price
    +0.370% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    43,922.25 Price
    -0.160% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    15,800.20 Price
    -0.510% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    XRP/USD

    0.64 Price
    +2.700% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading